4535-96-0

Upstream product

• 67-56-1 methanol 
• 77-55-4 1-phenyl-1-cyclopentanecarboxylic acid 
• 107-13-1 acrylonitrile 
• 186581-53-3 diazomethane 
• 101-41-7 benzeneacetic acid methyl ester 
• 77-57-6 1-phenyl-1-cyclopentanecarbonitrile 
• 17380-62-0 1-phenylcyclopentanecarboxylic acid chloride 

Downstream Products

• 136089-15-1 O-<2-<2-(diethylamino)ethoxy>ethyl>-1-phenyl-1-cyclopentanemethanol 
• 1026791-37-6 1-phenylcyclopentanecarboxylic acid (R)-(1-azabicyclo[2.2.2]oct-3-yl) ester 
• 635310-43-9 dimethyl 2-[1-(phenyl)cyclopentyl]-2-oxoethyl phosphonate 
• 77-55-4 1-phenyl-1-cyclopentanecarboxylic acid 
• 17380-62-0 1-phenylcyclopentanecarboxylic acid chloride 
• 1195983-05-1 (R)-3-(1-phenylcyclopentanecarbonyloxy)-1-(5-phenyl-[1,2,4]oxadiazol-3-ylmethyl)-1-azoniabicyclo[2.2.2]octane chloride 
• 1195983-04-0 (R)-3-(1-phenylcyclopentanecarbonyloxy)-1-(5-phenylisoxazol-3-ylmethyl)-1-azoniabicyclo[2.2.2]octane chloride 
• 59115-90-1 1-hydroxymethyl-1-phenylcyclopentane 

Relevant academic research and scientific papers

Achiral Derivatives of Hydroxamate AR-42 Potently Inhibit Class i HDAC Enzymes and Cancer Cell Proliferation

AR-42 is an orally active inhibitor of histone deacetylases (HDACs) in clinical trials for multiple myeloma, leukemia, and lymphoma. It has few hydrogen bond donors and acceptors but is a chiral 2-arylbutyrate and potentially prone to racemization. We report achiral AR-42 analogues incorporating a cycloalkyl group linked via a quaternary carbon atom, with up to 40-fold increased potency against human class I HDACs (e.g., JT86, IC50 0.7 nM, HDAC1), 25-fold increased cytotoxicity against five human cancer cell lines, and up to 70-fold less toxicity in normal human cells. JT86 was ninefold more potent than racAR-42 in promoting accumulation of acetylated histone H4 in MM96L melanoma cells. Molecular modeling and structure-activity relationships support binding to HDAC1 with tetrahydropyran acting as a hydrophobic shield from water at the enzyme surface. Such potent inhibitors of class I HDACs may show benefits in diseases (cancers, parasitic infections, inflammatory conditions) where AR-42 is active.

An improved bouveault-blanc ester reduction with stabilized alkali metals

Significantly improved Bouveault-Blanc conditions for ester reduction have been developed using sodium in silica gel (Na-SG), a free-flowing powder that can be easily handled in the open atmosphere. Primary alcohols were prepared in excellent yield from a variety of aliphatic esters under mild reaction conditions. The chemistry presented here is far safer than the classic Bouveault-Blanc reduction and is competitive with more modern hydride reduction methods.

Design and synthesis of novel imidazoline derivatives with potent antihyperglycemic activity in a rat model of type 2 diabetes

Imidazoline derivatives have been reported to show antihyperglycemic activity in vivo. In the present study, we first showed that there was no correlation between the in vivo antidiabetic activity and the in vitro affinities for the I1/I2

GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF

1,2-substituted 5-pyrrolidinone compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, renal dysfunction, an immune deficiency disorder, dry eye, ichthyosis, elevated intraocular pressure, sleep disorder, or gastric ulcer, inflammatory disorders and other diseases and disorders associated with the prostaglandin family of compounds.

Generation of 5- and 6-membered ring radicals by deoxygenation of alkoxy radicals

A new approach, based on deoxygenation of alkoxyl radicals with triphenylphosphine, for the formation of 5- and 6-membered ring radicals from acyclic radical precursors is described.

1-phenylalkanecarboxylic acid derivatives as anticonvulsant and neuroprotective agents

The compounds belong to the class of non-narcotic, non-opiate derivatives the 1-phenylalkanecarboxylic acid basic structure useful as anticonvulsant and neuroprotective agents. The compounds include novel derivatives as well as previously published species. Methods for controlling convulsions in a variety of pharmaceutical formulations and modalities are also provided.

Novel 1-phenylcycloalkanecarboxylic acid derivatives as potential anticonvulsant agents

A series of analogues based on the anticonvulsant carbetapentane (1, 2-[2- (diethylamino)ethoxy]ethyl 1-phenyl-1-cyclopentylcarboxylate) was prepared as potential novel anticonvulsant drugs. Structure-activity relationships of analogues in which the ester function and cyclopentane moieties were modified have been investigated by evaluating their ability to prevent seizures in the rat maximal electroshock test. These compounds (11, ED50 = 16 μmol/kg; 12, ED50 = 86 μmol/kg, and 23, ED50 = 173 μmol/kg) were effective anticonvulsants. Compound 11, an alkyl ether derivative of 1, was more potent than the parent compound (ED50 = 48 μmol/kg) and also showed a 2-fold increase in potency compared to that of the prototypic anticonvulsant drug diphenylhydantoin.